Nyxoah S.A. (NASDAQ:NYXH) Q2 2022 Results Conference Call August 8, 2022 4:30 PM ET

Company Participants

Jeremy Feffer - VP, IR

Olivier Taelman - CEO

Loic Moreau - CFO

Conference Call Participants

Ross Osborn - Cantor Fitzgerald

Simran Kaur - Piper Sandler

Suraj Kalia - OpCo

Operator

Good day, and thank you for standing by. Welcome to the Nyxoah Second Quarter ‘22 Conference Call. [Operator Instructions] Please be advised, today’s conference is being recorded.

I would like to hand the conference call to your speaker today, Jeremy Feffer, Vice President, Investor Relations. Please go ahead.

Jeremy Feffer

Thank you, James. Good afternoon, everyone, and welcome to our earnings call for the second quarter of 2022. Participating from the company today will be Olivier Taelman, Chief Executive Officer; and Loic Moreau, Chief Financial Officer.

During the call, we’ll discuss our operating activities and review our second quarter financial results released after U.S. markets closed today, after which we’ll host a question-and-answer session. The press release can be found on the Investor Relations section of our website, and this call is being recorded and will be archived in the Events section of our Investor Relations website.

Before we begin, I would like to remind you that any statements that relate to expectations or predictions of future events, market trends, results or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.

Our forward-looking statements are based upon currently available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors section of our Form 20-F filed with the Securities and Exchange Commission on March 24, 2022.

With that, I would like to turn the call over to Olivier.

Olivier Taelman

Thank you, Jeremy. Good afternoon, and good evening, everyone, and thank you for joining us for our second quarter 2022 earnings call. We continued to make excellent progress toward our key strategic objectives during the second quarter, and we are extremely well positioned as we move into the second half of 2022. As a reminder, our 3 key strategic priorities for this year are: completing the U.S. DREAM pivotal trial; accelerating commercial execution in Germany; and commencing of ACCCESS U.S. IDE study for complete concentric collapse, or CCC, patients before year-end.